



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

: Confirmation No. 9517

Tsuyoshi SUZUKI et al.

: Attorney Docket No. 2004_1909A

Serial No. 10/516,360

: Group Art Unit 1625

Filed March 4, 2005

: Examiner Taofiq A. Solola

PREVENTIVES AND/OR REMEDIES
FOR SUBJECTS WITH THE EXPRESSION OR
ACTIVATION OF Her2 AND/OR EGFR

: Mail Stop: AMENDMENT

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated December 31, 2007, Applicants hereby elect the invention identified as Group II (claims 19-24), drawn to a method; as a representative, N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-methyl-3-(4-methyl-1-piperazinyl)-1-butynyl]-6-quinazolinyl}acrylamide which is the penultimate compound presented in claim 16; and cancer as a specific disease.

Favorable action on the merits is now requested.

Respectfully submitted,

Tsuyoshi SUZUKI et al.

By:

Warren M. Cheek

Warren M. Cheek

Registration No. 33,367

Attorney for Applicants

WMC/WRS/lq
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
January 31, 2008